Session Details

This session explores the use of liquid biopsy—including circulating tumor DNA (ctDNA) and minimal residual disease (MRD) detection—to refine risk assessment and guide personalized, adaptive therapy across neoadjuvant, adjuvant, and metastatic breast cancer settings.

Presentation numberSA1-01

Neoadjuvant adaptive strategies: Integrating imaging and ctDNA to personalize preoperative therapy

Angela M DeMichele, University of Pennsylvania, Philadelphia, PA

Presentation numberSA1-02

MRD-informed adjuvant therapy: From risk stratification to personalized management

Michail Ignatiadis, Institut Jules Bordet, Brussels, Belgium

Presentation numberSA1-03

Guiding metastatic breast cancer treatment with pharmacodynamic and predictive liquid biopsy biomarkers

Francois-Clement Bidard, Institut Curie, Paris, France

Advocate

Tracy Edler Solak, Young Survival Coalition, Houston, TX